Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET.

OBJECTIVE Dopaminergic abnormalities in frontal-subcortical circuits have been hypothesized as the underlying pathophysiologic mechanism in Tourette's syndrome. The objective of this study was to test the hypothesis that presynaptic dopamine release from the striatum is abnormal in adults with Tourette's syndrome. METHOD Seven adults with Tourette's syndrome and five age-matched comparison subjects each received two positron emission tomography (PET) scans with high specific activity [11C]raclopride. The first scan followed an intravenous injection of saline; the second followed an intravenous injection of amphetamine. The relative dopamine release was estimated as the percentage difference in binding potential between the postsaline and postamphetamine scans. RESULTS Binding potential determined after the initial [11C]raclopride scan did not significantly differ between Tourette's syndrome and comparison subjects. After amphetamine challenge, the mean value of intrasynaptic dopamine in the putamen (as determined by true equilibrium bolus estimation) increased by 21% in the subjects with Tourette's syndrome and did not change in the comparison subjects; the mean values increased by 16.9% and decreased by 1.8%, respectively, when measured by the constrained method. Dopamine release in the caudate region was not significantly different in the Tourette's syndrome and comparison subjects. CONCLUSIONS Greater putamen dopamine release was seen in adults with Tourette's syndrome than in comparison subjects after a pharmacologic challenge with amphetamine. These results suggest that the underlying pathobiology in Tourette's syndrome is a phasic dysfunction of dopamine transmission.

[1]  M. Trimble,et al.  Dopamine receptor availability in Tourette's syndrome , 1994, Psychiatry Research: Neuroimaging.

[2]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[3]  H. Singer,et al.  The validity of instruments measuring tic severity in Tourette's syndrome. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[4]  E Stern,et al.  A functional neuroanatomy of tics in Tourette syndrome. , 2000, Archives of general psychiatry.

[5]  H. Singer,et al.  Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome , 1991, Annals of neurology.

[6]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[7]  N. Volkow,et al.  Long‐lasting inhibition of in vivo cocaine binding to dopamine transporters by 3β‐(4‐Iodophenyl)Tropane‐2‐Carboxylic acid Methyl Ester: RTI‐55 or βCIT , 1995, Synapse.

[8]  E. Chee,et al.  Volumetric MRI changes in basal ganglia of children with Tourette's syndrome , 1993, Neurology.

[9]  M. Millan,et al.  Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. , 1995, The Journal of pharmacology and experimental therapeutics.

[10]  J. Sirviö,et al.  Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum. , 1997, European journal of pharmacology.

[11]  Bradley S. Peterson,et al.  Course of Tic Severity in Tourette Syndrome: The First Two Decades , 1998, Pediatrics.

[12]  A. Gjedde,et al.  D2-like dopamine receptor density in Tourette syndrome measured by PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  R. Coppola,et al.  Tourette Syndrome: Prediction of Phenotypic Variation in Monozygotic Twins by Caudate Nucleus D2 Receptor Binding , 1996, Science.

[14]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Anderson,et al.  A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. , 1998, Archives of general psychiatry.

[16]  R. Albin,et al.  Striatal presynaptic monoaminergic vesicles are not increased in Tourette’s syndrome , 1999, Neurology.

[17]  N. Volkow,et al.  Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. , 1997, The American journal of psychiatry.

[18]  M. Millan,et al.  Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release , 1998, Neuroscience.

[19]  A. Rothner,et al.  Gilles de la Tourette's syndrome , 1985, Neurology.

[20]  B. Shaywitz,et al.  Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. , 1978, Archives of general psychiatry.

[21]  D. Wong,et al.  Column-switching HPLC for the analysis of plasma in PET imaging studies. , 2000, Nuclear medicine and biology.

[22]  M. Laruelle.  Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  H. Singer.  Current issues in Tourette syndrome , 2000, Movement disorders : official journal of the Movement Disorder Society.

[24]  B. Peterson,et al.  Reduced basal ganglia volumes in Tourette's syndrome using three‐dimensional reconstruction techniques from magnetic resonance images , 1993, Neurology.

[25]  P. Rabins,et al.  Serum haloperidol levels in Gilles de la Tourette syndrome. , 1981, Biological psychiatry.

[26]  R. Caprioli,et al.  Biogenic amine metabolism in tourette syndrome , 1979, Annals of neurology.

[27]  D. Wong,et al.  Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.

[28]  J. Coyle,et al.  Dopaminergic dysfunction in tourette syndrome , 1982 .

[29]  Reinhard Dengler,et al.  Dopamine transporter binding in Gilles de la Tourette syndrome , 2000, Journal of Neurology.

[30]  Alan C. Evans,et al.  MRI-PET Correlation in Three Dimensions Using a Volume-of-Interest (VOI) Atlas , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  D. Cohen,et al.  The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.

[32]  K. Kidd,et al.  Gilles de la Tourette's syndrome , 1986, Neurology.

[33]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[34]  H. Singer,et al.  Infection: a stimulus for tic disorders. , 2000, Pediatric neurology.

[35]  K. Starke,et al.  Presynaptic α2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[36]  Darin D Dougherty,et al.  Dopamine transporter density in patients with attention deficit hyperactivity disorder , 1999, The Lancet.

[37]  Neurobiology of Tourette syndrome , 1997 .

[38]  G. Stebbins,et al.  Adult tics in Gilles de la Tourette's syndrome , 1992, Neurology.

[39]  Andreas Heinz,et al.  Tourette's syndrome , 1998, Neurology.

[40]  D. Kupfer,et al.  Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria , 2001, Biological Psychiatry.

[41]  A. Gjedde,et al.  Dopamine transporter changes in neuropsychiatric disorders. , 1998, Advances in pharmacology.

[42]  G D Pearlson,et al.  PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. , 1997, The American journal of psychiatry.

[43]  M. Ernst,et al.  High presynaptic dopaminergic activity in children with Tourette's disorder. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[44]  C. McDougle,et al.  [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. , 1995, The American journal of psychiatry.

[45]  H. Singer,et al.  Tourette Syndrome and Other Tic Disorders Diagnosis, Pathophysiology, and Treatment , 1991, Medicine.

[46]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Meltzer,et al.  Quantification of Neuroreceptors in the Living Human Brain: III. D2-Like Dopamine Receptors: Theory, Validation, and Changes during Normal Aging , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  D. Cohen,et al.  Brain monoamines and amino acids in Gilles de la Tourette's syndrome: a preliminary study of subcortical regions. , 1992, Archives of general psychiatry.